Eton PharmaceutcialsETON
Market Cap: $152M
About: Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Employees: 30
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
4,075% more call options, than puts
Call options by funds: $167K | Put options by funds: $4K
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
14% more capital invested
Capital invested by funds: $26.9M [Q1] → $30.8M (+$3.89M) [Q2]
8.51% more ownership
Funds ownership: 27.96% [Q1] → 36.47% (+8.51%) [Q2]
2% more funds holding
Funds holding: 43 [Q1] → 44 (+1) [Q2]
63% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 16
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 35 / 117 met price target | 53%upside $9 | Buy Assumed | 4 Sept 2024 |